 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...6789101112131415161718 |
- ||||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Trial primary completion date: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Sep 29, 2015
P3, N=232, Active, not recruiting, Sponsor: Pharmacyclics
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Feb 2018
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Sep 24, 2015
P1, N=30, Recruiting, Sponsor: TG Therapeutics, Inc.
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Feb 2018 Trial primary completion date: Oct 2015 --> Feb 2016
- Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Trial primary completion date: Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma (clinicaltrials.gov) - Aug 25, 2015
P3, N=450, Active, not recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Trial primary completion date: Oct 2015 --> Feb 2016 Trial primary completion date: Jun 2015 --> Jun 2017
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Aug 21, 2015
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2015 --> Jun 2017 Trial primary completion date: Jun 2017 --> Sep 2017
- |||||| Calquence (acalabrutinib) / AstraZeneca
Enrollment open, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Jul 19, 2015
P3, N=510, Recruiting, Sponsor: Acerta Pharma BV
Trial primary completion date: Jun 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Trial primary completion date: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - Jul 2, 2015
P4, N=26, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2018 --> Feb 2019
- |||||||||| Calquence (acalabrutinib) / AstraZeneca
New P3 trial, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Jun 20, 2015
P3, N=510, Not yet recruiting, Sponsor: Acerta Pharma BV
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Jun 3, 2015
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- ||| Zydelig (idelalisib) / Gilead
Trial completion, Combination therapy, Immunomodulating: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 13, 2015
P1, N=241, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 3, 2015
P1, N=30, Recruiting, Sponsor: TG Therapeutics, Inc.
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Oct 2015
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
New P1 trial: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Jan 12, 2015
P1, N=60, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Zydelig (idelalisib) / Gilead
Trial primary completion date, Combination therapy, Immunomodulating: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 17, 2014
P1, N=224, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: May 2015 --> Oct 2015 Trial primary completion date: Jun 2016 --> Apr 2015
- Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Dec 12, 2014
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial primary completion date: Jun 2016 --> Apr 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- |||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 9, 2014
P3, N=432, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Recruiting
- |||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Oct 22, 2014
P3, N=212, Recruiting, Sponsor: Pharmacyclics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
New P3 trial, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Oct 17, 2014
P3, N=212, Not yet recruiting, Sponsor: Pharmacyclics
- Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open, Combination therapy: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - Oct 10, 2014
P2, N=112, Recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
New P3 trial: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 19, 2014
P3, N=432, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - Aug 21, 2014
P4, N=26, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=200 --> 26 | Trial primary completion date: Jul 2017 --> Jan 2015
- |||| Leukeran (chlorambucil) / GSK
Trial primary completion date: Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (clinicaltrials.gov) - Jul 10, 2014
P3, N=450, Active, not recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting | N=200 --> 26 | Trial primary completion date: Jul 2017 --> Jan 2015 Trial primary completion date: Jul 2013 --> Mar 2018
- ||||| Leukeran (chlorambucil) / GSK
Trial initiation date, Trial primary completion date: Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (clinicaltrials.gov) - Jul 10, 2014
P3, N=450, Active, not recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Jul 2013 --> Mar 2018 Initiation date: May 2009 --> Nov 2009 | Trial primary completion date: Jul 2013 --> Mar 2018
- || lenalidomide / Generic mfg.
Trial primary completion date: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Jun 19, 2014
P2, N=254, Active, not recruiting, Sponsor: Celgene Corporation
Initiation date: May 2009 --> Nov 2009 | Trial primary completion date: Jul 2013 --> Mar 2018 Trial primary completion date: May 2014 --> Mar 2017
- || Zydelig (idelalisib) / Gilead
Enrollment closed, Combination therapy, Immunomodulating: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 29, 2014
P1, N=224, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: May 2014 --> Mar 2017 Recruiting --> Active, not recruiting
- | Ukoniq (umbralisib) / TG Therap
New P1 trial, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 30, 2014
P1, N=30, Recruiting, Sponsor: TG Therapeutics, Inc.
- Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Trial initiation date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting --> Active, not recruiting Initiation date: Jun 2013 --> Oct 2013
- Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Enrollment open: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Initiation date: Jun 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- |||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 25, 2013
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial initiation date, Combination therapy: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - Nov 21, 2013
P2, N=112, Not yet recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Not yet recruiting --> Recruiting Initiation date: Mar 2013 --> Dec 2013
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen
New P3 trial, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jul 21, 2013
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Leukeran (chlorambucil) / GSK
Enrollment closed: Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (clinicaltrials.gov) - Apr 22, 2013
P3, N=450, Active, not recruiting, Sponsor: Celgene Corporation
Initiation date: Mar 2013 --> Dec 2013 Completed --> Active, not recruiting
- ||| lenalidomide / Generic mfg.
Enrollment closed: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Mar 10, 2013
P2, N=254, Active, not recruiting, Sponsor: Celgene Corporation
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- | Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
New P2 trial, Combination therapy: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - Mar 7, 2013
P2, N=112, Not yet recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
- ||||| Arzerra (ofatumumab) / Novartis, Genmab
Enrollment closed, Monotherapy: COMPLEMENT 1: Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 30, 2013
P3, N=447, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Nov 7, 2012
P3, N=272, Enrolling by invitation, Sponsor: Pharmacyclics
- || Arzerra (ofatumumab) / Novartis, Genmab
New P3 trial: RIAltO: A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (clinicaltrials.gov) - Sep 3, 2012
P3, N=670, Recruiting, Sponsor: University of Liverpool
- |||||||||| bendamustine / Generic mfg.
New P3 trial: Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 2, 2012
P3, N=96, Recruiting, Sponsor: Shandong Lanjin Pharmaceuticals Co.,Ltd
- || Zydelig (idelalisib) / Gilead
Enrollment change, Combination therapy, Immunomodulating: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 17, 2012
P1, N=224, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting N=150 --> 224
- |||| Rituxan (rituximab) / Roche
Enrollment open: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - Oct 17, 2011
P4, N=200, Recruiting, Sponsor: Hoffmann-La Roche
N=150 --> 224 Not yet recruiting --> Recruiting